Scopia Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Scopia Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-54,942	Closed	-$6.81M	–	35
2019 Q4	$6.81M	Sell	54,942 -1,852	-3%	-$166K	0.53%	19
2019 Q3	$3.77M	Hold	56,794	–	–	0.22%	22
2019 Q2	$4.52M	Buy	+56,794	New	+$5.08M	0.2%	22
2019 Q1	–	Sell	-64,961	Closed	-$6.55M	–	33
2018 Q4	$6.55M	Hold	64,961	–	–	0.22%	25
2018 Q3	$8.21M	Hold	64,961	–	–	0.16%	34
2018 Q2	$5.45M	Hold	64,961	–	–	0.1%	35
2018 Q1	$4M	Buy	+64,961	New	+$3.91M	0.08%	30

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Scopia Capital Management's ICPT Position: Q1 2020 in Review

Scopia Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2020, closing a stake of 54,942 shares — an estimated $6.81M sold.

Scopia Capital Management first reported a position in ICPT in Q1 2018 and held it in 7 quarters. The position peaked at $8.21M in Q3 2018. 188 funds tracked by Wall St. Rank hold ICPT as of Q1 2020.

Scopia Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Scopia Capital Management sold 54,942 Intercept Pharmaceuticals, Inc. shares in Q1 2020, an estimated $6.81M.
Scopia Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2018 and held it in 7 quarters.
Scopia Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $8.21M in Q3 2018.
188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2020.

Based on Scopia Capital Management's 13F filing for Q1 2020, filed 15 May 2020.